COMPLI™

A Global Compliance Standard for High-Risk Services

Connect more easily with providers of high-risk services in a more compliant manner

COMPLI™ is a global process for the sourcing of high-risk research services, such as the acquisition of human biological samples (HBS), secondary real-world evidence (RWE) and health economics and outcomes research (HEOR), among others. Created in partnership with leading pharmaceutical companies and suppliers, COMPLI™ introduces an appropriate due diligence process and service specific supply agreement supporting access to relevant higher risk services. Now, researchers in the pharmaceutical and biotech industries and academia can more easily connect with providers of high-risk services in a manner compliant with their internal policies and procedures.

Background

COMPLI™ is comprised of three core features, ensuring the greatest chance of full compliance.

Due Diligence

Service specific due diligence simplifies and speeds up the evaluation process of suppliers to confirm they meet internal client compliance policies and procedures.

Pre-Approved Agreement

A service specific agreement offers a pre-agreed upon contract that has been approved by pharma and suppliers.

Compliance Manager

The Compliance Manager establishes a rigorous compliance and governance framework that increases visibility, traceability and control for the client.

COMPLI™ is already having significant impact on high-risk services—human biospecimens, such as organs, tissues and genetic material, are increasingly being used in drug research, but until now there has been no common process supporting their acquisition. The new COMPLI™ process helps researchers and suppliers adhere to internal and external (often legislative) procurement policies. It also ensures that appropriate donor consents have been obtained, tracked and communicated throughout the supply chain.

Background

COMPLI™ establishes a rigorous compliance and governance framework that increases visibility, traceability and control for the biopharma industry.

It is only available through the Scientist.com marketplace.